NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 18 hours 22 min ago

CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)

Wed, 12/20/2017 - 03:30
Funding Opportunity PAR-18-543 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Categories: NIH-Funding

NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional)

Wed, 12/20/2017 - 03:29
Funding Opportunity PAR-18-542 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Categories: NIH-Funding

Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed)

Wed, 12/20/2017 - 02:29
Funding Opportunity RFA-TR-18-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for the Tissue Chip Testing Center (TCTC) Microphysiological Systems (MPS) Data Center (MPS DC), which supports the NIH Tissue Chip Consortium. The Consortium facilitates the development, validation and dissemination of tissue chip (TC) technology through support for collaborative research in 1) development of tissue chips for toxicity and safety testing of promising therapeutics (RFA-RM-11-022); 2) development of tissue chips for disease modeling and efficacy testing (RFA-TR-16-017 and RFA-TR-16-019); and 3) independent validation of tissue chip platforms through the TCTCs (RFA-TR-16-006). The MPS DC is expected to be the central clearinghouse for TC data management, and will incorporate novel approaches and technologies for data management, data mining and meta-analyses, and data sharing across many organs and tissues, diseases, data types, and TC platforms. The MPS Data center is expected to provide different levels of public and tiered access to TC information for basic and clinical researchers, academic and practicing physicians, the pharmaceutical industry, NIH, FDA and other government agencies, patients, and the lay public. The MPS Data Center will work with IQ Consortium members to develop and make available a secure, customizable coordinated data management system for collection, storage, and analyses of diverse data types from multiple TC platforms being developed and used for drug screening, safety and efficacy testing.
Categories: NIH-Funding

NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)

Wed, 12/20/2017 - 02:29
Funding Opportunity RFA-TR-18-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for NextGen Tissue Chip Testing Center(s) (NextGen TCTC) that will provide resources and infrastructure for the validation of tissue chips being developed as part of the NIH Tissue Chip (TC) for Drug Screening Program or NIH Microphysiological Systems (MPS) Program. The MPS program supports a consortium of investigators developing accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity (RFA-RM-11-022; RFA-TR-16-017; RFA-TR-16-019). The developed in vitro MPS platforms are representative of major organs and tissues in the human body, and need to be validated for their predictive capabilities of the assessment of biomarkers, and the bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Validation of the tissue chips is currently being conducted through Tissue Chip Testing Centers. These are responsible for testing a select group of compounds using predefined assays and biomarkers, according to pharmaceutical industry standards, and the integration of the data into a public database. NextGen TCTC(s) will aim to accelerate the transition of NIH-supported research innovations and technologies toward a self-sustaining model to continue the validation of various MPS platforms. NextGen TCTC(s) will develop services that promote the use of MPS by industry, regulatory bodies, and biotech sectors, and create significant value and economic stimulus or, advance the research in MPS technology in a way that could stimulate future growth and investments, and advance drug discovery and development. This U24is intended to support research and development (R and D) specifically targeted at activities that can help address the funding gap between promising R and D and transitioning to the market, often called the Valley of Death by contributing the critical funding needed by applicants to pursue the next appropria
Categories: NIH-Funding

Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed)

Tue, 12/19/2017 - 13:57
Funding Opportunity PA-18-525 from the NIH Guide for Grants and Contracts. The purpose of this Founding Opportunity Announcement (FOA) is to encourage new or renewal Small Business Innovation Research (SBIR) grant applications focused on specific product development activities for radiological/nuclear medical countermeasures leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission packages to the U.S. Food and Drug Administration.
Categories: NIH-Funding

Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 - Clinical Trial Optional)

Tue, 12/19/2017 - 13:21
Funding Opportunity PA-18-508 from the NIH Guide for Grants and Contracts. Funding Opportunity Purpose This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is intended to support novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Categories: NIH-Funding

Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 - Clinical Trial Optional)

Tue, 12/19/2017 - 13:20
Funding Opportunity PA-18-507 from the NIH Guide for Grants and Contracts. Funding Opportunity Purpose This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is intended to support novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Categories: NIH-Funding

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)

Tue, 12/19/2017 - 13:11
Funding Opportunity PA-18-517 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.
Categories: NIH-Funding

Revision: NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects

Tue, 12/19/2017 - 12:24
Notice NOT-OD-18-116 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NIH Operates Under a Continuing Resolution Through December 22, 2017

Tue, 12/19/2017 - 10:11
Notice NOT-OD-18-120 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)

Tue, 12/19/2017 - 10:07
Funding Opportunity RFA-DK-17-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.
Categories: NIH-Funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)

Tue, 12/19/2017 - 10:06
Funding Opportunity RFA-DK-17-018 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. This FOA is intended to support highly exploratory studies which may require development and testing of novel experimental platforms or analytic methods. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.
Categories: NIH-Funding

Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Projects

Tue, 12/19/2017 - 10:00
Notice NOT-OD-17-071 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed)

Tue, 12/19/2017 - 03:38
Funding Opportunity PAR-18-516 from the NIH Guide for Grants and Contracts. The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimers disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells is essential to understanding the etiology of AD.
Categories: NIH-Funding

Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional)

Tue, 12/19/2017 - 02:02
Funding Opportunity PAR-18-511 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage grant applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy.
Categories: NIH-Funding

Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional)

Mon, 12/18/2017 - 13:55
Funding Opportunity PAR-18-506 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations.
Categories: NIH-Funding